Hubertus von Baumbach, Boehringer Ingelheim's chairman of the board of managing directors, at its annual press conference on April 16, 2024 (Arne Dedert/picture-alliance/dpa/AP Images)
April 16, 2024 07:43 AM EDTUpdated April 30, 10:56 AM
Pharma

Cor­rec­tion: Boehringer In­gel­heim touts 10-year plan as it eyes over­tak­ing Bay­er as Ger­many’s largest phar­ma

Ayisha Sharma

News Reporter

Anna Brown

News Reporter

Boehringer In­gel­heim put the spot­light on a pipeline ripe with mile­stones over the next decade dur­ing its full-year 2023 call with the press.

Dri­ven in …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

FDA ap­proves Io­n­is’ treat­ment for a rare meta­bol­ic dis­or­der

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

A service from the Financial Times